Weekly Digest – February 2026 Weekly Digest – February 2026 16 February 2026: Novartis Pluvicto (lutetium (177Lu) vipivotide tetraxetan) receives MHRA authorisation for new indication for eligible patients with PSMA‑positive metastatic castration‑resistant prostate cancer Novartis announced that the UK Medicines […]
Weekly Digest – February 2026 Weekly Digest – February 2026 19 February 2026: ENHERTU Type II Variation Application validated in the EU as post-neoadjuvant treatment for patients with HER2 positive early breast cancer The European Medicines Agency has validated a […]
Weekly Digest – February 2026 Weekly Digest – February 2026 14 February 2026: Hengrui Medicine’s HER2 ADC, Trastuzumab Ruikang, has been included in the Breakthrough Therapy List for a new indication Hengrui Medicine announced that its independently developed HER2-targeting antibody–drug […]
Weekly Digest – February 2026 Weekly Digest – February 2026 14 February 2026: Alphamab Oncology announces the first patient dosed in a phase 3 clinical study for colorectal cancer of biparatopic HER2-targeting ADC JSKN003 Alphamab Oncology announced that the first […]
Weekly Digest – February 2026 Weekly Digest – February 2026 17 February 2026: BostonGene announces strategic collaboration with Daiichi Sankyo to accelerate drug development through AI-driven multimodal analytics BostonGene announced a strategic collaboration with Daiichi Sankyo to integrate AI-driven multimodal […]
Weekly Digest – February 2026 Weekly Digest – February 2026 19 February 2026: Affibody signs Letter of Intent with SHINE Technologies for supply of Lutetium-177 Affibody announced that it has signed a Letter of Intent with SHINE Technologies to secure […]
